DermoSight (dermatoscope)

2023: Device Announcement

On June 6, 2023, DeepX Diagnostics announced the release of an innovative DermoSight device designed to detect skin cancer without biopsy. The system is based on a patented technology with artificial intelligence algorithms.

It is noted that skin cancer is the most common type of malignancy in the world. In the United States alone, the disease manifests itself annually in 6.1 million people. If detected early, skin cancer can be effectively eliminated by removing the formation by a relatively simple surgical procedure. However, in the absence of therapy, metastatic skin cancer is fatal in most patients.

DermoSight

DermoSight is a digital dermatoscope for screening for malignant skin lesions. The device integrates with an AI platform based on OTD (Optical Transfer Diagnosis) technology. The principle of its work boils down to the identification of possible lesions at the subcutaneous level based on the light-transmitting properties of tissues. DeepX Diagnostics states that the DermoSight system is able to turn dermatoscopic evaluation into a reliable, non-invasive and affordable AI tool for investigating skin lesions. This will help people with suspected skin cancer get early diagnosis and effective treatment.

DeepX Diagnostics emphasizes that skin malignancies are usually diagnosed by dermatologists by biopsy, which means long waiting times, as well as the use of expensive and invasive procedures. The DermoSight system allows you to bypass all these shortcomings. Moreover, the result in accuracy, as stated, is not inferior to other clinical methods. In general, according to the developer, the technology can revolutionize the approach to diagnosing skin cancer.^[1]

Notes